Objectives: To estimate the proportion and number of cancers occurring in Australia in 2010 attributable to combined oral contraceptive pill (OCP) use.
T he combined oral contraceptive pill (OCP) was first introduced in Australia in the early 1960s. Although there are many varieties and doses available, all contain an oestrogen and a progestogen. They prevent pregnancy principally by stopping ovulation, although their contraceptive effects are also mediated through changes to cervical mucus and the endometrium. 1 Oestrogens and progestogens in combination can increase or decrease cell proliferation, depending on the target tissue, and it is likely that these effects are responsible for at least some of the observed associations with cancers described below.
The International Agency for Research on Cancer (IARC) in its 2008 review of 20 pharmaceutical agents concluded that there was sufficient evidence that combined oral contraceptives cause cancer of the breast, uterine cervix and liver. 1 They also concluded that use of the combined OCP reduces the risk of endometrial and ovarian cancer. The level of risk associated with each cancer type varies by duration and recency of oral contraceptive use and is summarised in Table 1 .
We aimed to estimate the overall number and proportion of cancers diagnosed in 2010 that could be attributed to combined OCP use, as well as the proportion and number of cancers that have -in theory -been prevented by its use. In our primary analysis, we calculated estimates for cancers of the breast and uterine cervix. We did not include liver cancer because it appears that once exposure to the combined OCP has stopped there is no persisting increase in risk. 2 As liver cancer is extremely uncommon in women under the age of 50 in Australia, the number of cases attributable to current combined OCP use would be trivial. We also estimated the numbers and fractions of endometrial and ovarian/fallopian tube cancers (many ovarian cancers may actually arise from the fallopian tube) prevented (avoided) through use of combined OCPs.
Methods
The population attributable fraction of cancers associated with OCP use is the proportion of cancers diagnosed in a given period in a specified population that could potentially have been avoided if no one in the population had used the OCP. 3 We ) and a large, multi-centre prospective cohort study 7 (for endometrial cancer). The latter was the only study to have reported a dose-response relative risk, enabling duration of OCP use to be assessed in our calculations. The estimates of relative risk associated with combined OCP use for all four cancers are summarised in Table 1 .
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Exposure prevalence estimates
No latent period has been assumed in relation to this exposure. For cervical cancer, risk increases with duration of use and declines after cessation of use. For breast cancer, risk is among current and recent users only. As we did not have access to prevalence data by time since last use of OCPs or duration of use among current users, we modelled the PAF using relative risks for current versus never use, restricting our analyses to women under 50 years of age, as OCP use would be rare above this age. For endometrial and ovarian cancer, the protective effects increase with duration of use among ever-users and the effects appear to persist for at least two decades after stopping use, 1 so we modelled the effects of total duration of use regardless of whether this was current or past.
The most recent nationally representative data regarding current use of OCPs come from the 2001 National Health Survey Confidentialised Unit Record Files. 8 Women aged 18-49 years were asked whether they had ever used the contraceptive pill, if they were currently using the contraceptive pill, and the age that they had first started using the pill. 9 We used these data and assumed that the proportion of women (aged 18-49 years) currently using oral contraceptives remained stable over the ensuing decade to 2010. 
Statistical analysis
For breast and cervical cancer, the relative risks were for current versus never use of combined OCPs. For these cancers, the PAF was calculated using the following formula:
where p x is the proportion of Australian women currently using oral contraceptives in each age category x, and ERR x is the excess relative risk (RR x -1) for current use (for each of the respective cancers).
To obtain the number of cancers attributable to combined OCP use, the PAF was multiplied by the number of incident cancers at that site in 2010 13 for each age category (using the latest incidence data available from the Australian Institute of Health and Welfare). To estimate the number of cancers that would have occurred, but were prevented through use of combined OCPs, the following formula was used:
where N x is the observed number of cancers in 2010 in each age category and PF x is the prevented fraction in each age category.
The sum of the estimated numbers of cancers prevented across each age category is then expressed as a percentage of the total number of cancers expected in the absence of any protection (i.e. number observed + number prevented).
Results
More than one-quarter of all women aged 18 to 49 years surveyed in the 2001 NHS were currently taking the OCP. This proportion was highest (about 41%) in women aged under 30 years, declining steadily to 8% in women aged 45-49 years (Table 2 ).
In the AOCS control group, 25% of women had never used OCPs. This proportion varied by age, ranging from 6.9% in the 40-44 year age group to 63% in women aged over 70 years. More than 20% of all women had used oral contraceptives for between 10 and 20 years; 5.5% had used OCPs for more than 20 years (Table 2) .
We estimated that 157 cancers (105 breast and 52 cervical) in Australian women younger than 50 years of age could be attributed to current use of combined OCPs in 2010 (0.7% and 6.4% of all breast and cervical cancers, respectively, and 3.2% and 12.3% of those in women aged under 50 years). This was 0.3% of all cancers (excluding basal cell carcinoma and squamous cell carcinoma of the skin) diagnosed in women in 2010 and 1.7% of all cancers diagnosed in women aged under 50 years (Table 3) .
In contrast, an estimated 31% of endometrial cancers and 19% of ovarian cancers that would otherwise have occurred in 2010 were prevented through combined OCP use (Table 3) . This suggests that, in the absence of the combined OCP, an additional 1,032 endometrial cancers and 308 ovarian cancers would have been diagnosed in 2010.
Discussion
In ). Estimates for the other cancers were not reported in the French study, but for the UK study the PAF for cervical cancer was slightly higher at 9.7% and for ovarian and endometrial cancer the UK estimates were somewhat lower (16.9% and 9.3% respectively).
14 The UK PAF project had prevalence data on current use, past use and time since last use of oral contraceptives, 14 so the difference may reflect the ways in which prevalence data were applied. It is also possible that there are differences in patterns of duration of use between the populations; however, comparable data are not available for us to assess this.
The exact mechanisms whereby the combined OCP contributes to carcinogenesis is not completely clear, but there are several possibilities. Oestrogens and progestogens induce breast cell proliferation, particularly when both hormones are present. 16 In general, the breasts of women taking the combined OCP are exposed to the combined proliferative effects of oestrogen and progestogens for longer per cycle than those not taking the OCP, possibly increasing the risk of DNA damage and neoplastic transformation. The cumulative greater exposure to combined oestrogen and progestogen may also be important for cervical cancer. Cervical cancer is caused by human papillomavirus but, among women with the virus, oestrogens and progestogens may enhance expression of some HPV genes and may promote cervical cell proliferation, increasing the likelihood of neoplastic transformation. 2 Several processes may contribute to the protective effect of combined OCPs on ovarian/fallopian tube cancer. 2 This may be through direct hormonal effects such as reductions in gonadotrophins 17 and androgens 18 or the apoptotic effects of potent synthetic progestogens; 18 or through suppression of the physical effects of ovulation itself, 19 with concomitant reductions in exposure of the ovarian/ fallopian tube epithelium to inflammatory or hormonal factors that could result in neoplastic changes. The combined OCP also reduces retrograde menstruation, which has also been implicated in ovarian carcinogenesis.
The chemoprotective effects of oral contraceptives on endometrial cancer probably result from the effects of the progestogen component of combined OCPs. Although oestrogens stimulate proliferation of endometrial cells, they do this only in the absence of a progestogen. Progestogens induce terminal differentiation in endometrial cells so that they no longer proliferate and the risk of neoplastic transformation is reduced.
2,16
The major limitation of our analyses was the lack of contemporary comprehensive prevalence data for OCP use in Australia. Our data for current use were sourced from the 2001 National Health Survey and, although those data should represent the true population prevalence in 2001, we had to assume that there had been no major changes in usage patterns between 2001 and 2010. While this is probably a reasonable assumption, alternative contraceptive methods such as progestogen-releasing implants and intrauterine devices have become available in Australia in the last 10-15 years, and usage of these may be increasing and displacing the combined OCP. 20 Perhaps more uncertain is the reliability of the data we used for duration of OCP use, which was necessary to estimate the prevented fractions of ovarian and endometrial cancer. The only contemporary Australian source of these data was the population-based control group recruited between 2003 and 2006 for the Australian Ovarian Cancer Study. The participation proportion among potential controls was about 50% and, as the proportion of ever-users was higher in the AOCS control women than in the NHS, it is possible that our estimates for duration of use were also higher than the general population. Thus, we may have overestimated the prevented fractions for endometrial and ovarian cancer. We were also unable to assess the effects of time since stopping the OCP and we therefore assumed that risk of breast and cervical cancer returns to normal Moreover, long-term use of oral progestogens is uncommon, so the effect on our estimates is likely to have been small.
Overall, our analyses suggest that the use of combined OCPs confers far more benefit than harm with respect to cancer incidence, with a modest increase in the number of breast/ cervical cancer cases weighed against a much larger decrease in numbers of endometrial and ovarian cancers. However, along with small increases in cancer, the combined OCP can have other adverse effects such as thromboembolic disease, so its broad use as a cancer chemopreventive agent cannot be promoted. Women seeking contraceptive advice should be advised not only of the potential adverse effects but also that, along with its benefits to reproductive health, use of the combined OCP can reduce their longterm risk of ovarian and uterine cancers.
